Preclinical efficacy of drugs identified by IBM-Watson for repurposing to treat L-DOPA-induced dyskinesia

被引：0
|
作者：
Visanji, N.
Lacoste, A.
Ravenscroft, P.
Spangler, S.
Fox, S.
Lang, A.
Brotchie, J.
Johnston, T.
机构：
来源：
MOVEMENT DISORDERS | 2019年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
225
引用
收藏
页码：S94 / S94
页数：1
相关论文
共 50 条
  • [1] Repurposing drugs to treat L-DOPA-induced dyskinesia in Parkinson's disease
    Johnston, Tom H.
    Lacoste, Alix M. B.
    Visanji, Naomi P.
    Lang, Anthony E.
    Fox, Susan H.
    Brotchie, Jonathan M.
    [J]. NEUROPHARMACOLOGY, 2019, 147 : 11 - 27
  • [2] Using artificial intelligence to identify drugs for repurposing to treat L-DOPA-induced dyskinesia
    Johnston, Tom H.
    Lacoste, Alix M. B.
    Ravenscroft, Paula
    Su, Jin
    Tamadon, Sahar
    Seifi, Mahtab
    Lang, Anthony E.
    Fox, Susan H.
    Brotchie, Jonathan M.
    Visanji, Naomi P.
    [J]. NEUROPHARMACOLOGY, 2024, 248
  • [3] Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia
    Bartlett, Mitchell J.
    Flores, Andrew J.
    Ye, Tony
    Smidt, Saskia, I
    Dollish, Hannah K.
    Stancati, Jennifer A.
    Farrell, Drew C.
    Parent, Kate L.
    Doyle, Kristian P.
    Besselsen, David G.
    Heien, Michael L.
    Cowen, Stephen L.
    Steece-Collier, Kathy
    Sherman, Scott J.
    Falk, Torsten
    [J]. EXPERIMENTAL NEUROLOGY, 2020, 333
  • [4] L-DOPA-induced dyskinesia
    Derkinderen, P
    Vidailhet, M
    [J]. REVUE NEUROLOGIQUE, 2002, 158 : S92 - S101
  • [5] Dyskinesia: L-dopa-induced and tardive dyskinesia
    Rascol, O
    Fabre, N
    [J]. CLINICAL NEUROPHARMACOLOGY, 2001, 24 (06) : 313 - 323
  • [6] Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update
    AlShimemeri, Sohaila
    Fox, Susan H.
    Visanji, Naomi P.
    [J]. EXPERT OPINION ON EMERGING DRUGS, 2020, 25 (02) : 131 - 144
  • [7] Nalbuphine Efficacy for L-Dopa-induced Dyskinesia in Parkinson Disease
    Mouradian, M. Maral
    Papa, Stella M.
    Voronkov, Michael
    Braithwaite, Steven P.
    [J]. NEUROTHERAPEUTICS, 2016, 13 (03) : 650 - 650
  • [8] Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia
    Perez-Lloret, Santiago
    Rascol, Olivier
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2018, 125 (08) : 1237 - 1250
  • [9] Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia
    Santiago Perez-Lloret
    Olivier Rascol
    [J]. Journal of Neural Transmission, 2018, 125 : 1237 - 1250
  • [10] The pathophysiology of L-DOPA-induced dyskinesia
    Brotchie, JM
    [J]. MOVEMENT DISORDERS, 2004, 19 : S11 - S11
12345